JMP Securities Reiterates Market Outperform on Aquestive Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating for Aquestive Therapeutics (NASDAQ:AQST) and maintained a $9 price target.
August 12, 2024 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating for Aquestive Therapeutics and maintained a $9 price target.
The reiteration of a Market Outperform rating and the maintenance of a $9 price target by JMP Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100